Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/110751
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Callejo Castillo, Àngela | - |
dc.contributor.author | Sedó Cabezón, Lara | - |
dc.contributor.author | Doménech Juan, Ivan | - |
dc.contributor.author | Llorens i Baucells, Jordi | - |
dc.date.accessioned | 2017-05-10T10:19:33Z | - |
dc.date.available | 2017-05-10T10:19:33Z | - |
dc.date.issued | 2015-07-15 | - |
dc.identifier.issn | 2305-6304 | - |
dc.identifier.uri | http://hdl.handle.net/2445/110751 | - |
dc.description.abstract | Cisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ malignancies. However, serious side effects have been associated with its use, such as bilateral, progressive, irreversible, dose-dependent neurosensory hearing loss. Current evidence indicates that cisplatin triggers the production of reactive oxygen species in target tissues in the inner ear. A variety of agents that protect against cisplatin-induced ototoxicity have been successfully tested in cell culture and animal models. However, many of them interfere with the therapeutic effect of cisplatin, and therefore are not suitable for systemic administration in clinical practice. Consequently, local administration strategies, namely intratympanic adminis- tration, have been developed to achieve otoprotection, without reducing the antitumoral effect of cisplatin. While a considerable amount of pre-clinical information is available, clinical data on treatments to prevent cisplatin ototoxicity are only just beginning to appear. This review summarizes clinical and experimental studies of cisplatin ototoxicity, and focuses on understanding its toxicity mechanisms, clinical repercussions and prevention strategies. | - |
dc.format.extent | 26 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/toxics3030268 | - |
dc.relation.ispartof | Toxics, 2015, vol. 3, p. 268-293 | - |
dc.relation.uri | https://doi.org/10.3390/toxics3030268 | - |
dc.rights | cc-by (c) Callejo, Angela et al., 2015 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Fisiològiques) | - |
dc.subject.classification | Cisplatí | - |
dc.subject.classification | Medicaments antineoplàstics | - |
dc.subject.classification | Efectes secundaris dels medicaments | - |
dc.subject.classification | Toxicitat dels medicaments | - |
dc.subject.classification | Trastorns auditius | - |
dc.subject.classification | Sordesa | - |
dc.subject.classification | Ressenyes sistemàtiques (Investigació mèdica) | - |
dc.subject.other | Cisplatin | - |
dc.subject.other | Antineoplastic agents | - |
dc.subject.other | Drug side effects | - |
dc.subject.other | Drug toxicity | - |
dc.subject.other | Hearing disorders | - |
dc.subject.other | Deafness | - |
dc.subject.other | Systematic reviews (Medical research) | - |
dc.title | Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 655807 | - |
dc.date.updated | 2017-05-10T10:19:34Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 29051464 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Centres Científics i Tecnològics de la Universitat de Barcelona (CCiTUB)) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
655807.pdf | 574.53 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License